Tags

Type your tag names separated by a space and hit enter

Ipsilateral and Concurrent Breast Cancer and Atypical Ductal Hyperplasia: Does Atypia Also Need Surgical Excision?
Ann Surg Oncol. 2020 Nov; 27(12):4786-4794.AS

Abstract

BACKGROUND

Standard-of-care management of atypical ductal hyperplasia (ADH) is surgical excision. Multiple studies have identified features of ADH in patients at low risk for upgrade who may benefit from omission of surgical excision. Patients with an ipsilateral breast cancer have been excluded from studies investigating observation for the management of ADH.

METHODS

This was a retrospective review of women with both a breast cancer and an ipsilateral separate site of ADH diagnosed on percutaneous biopsy, who underwent excision of both sites from 2008 to 2018. Radiographic and pathologic features of ADH and cancer were analyzed, including imaging size, biopsy modality, distance between sites, cancer subtype, grade, prognostic markers, ADH foci, and presence of necrosis or micropapillary features. Final pathology at the ADH site was used to determine upgrade. Multivariable logistic regression was performed to identify variables significantly associated with ADH upgrade to malignancy.

RESULTS

Among 62 women meeting the inclusion criteria, 11 (17.7%) upgraded to malignancy [9 ductal carcinoma in situ (DCIS), 2 invasive cancer] at the site of ADH. Upgrade was significantly higher with ipsilateral DCIS (p = 0.03), ultrasound biopsy at the ADH site (p = 0.01), and ADH with necrosis (p = 0.04). The group at lowest risk for upgrade had stereotactic biopsy and ADH without necrosis (0% upgrade).

CONCLUSION

The presence of breast cancer does not significantly increase the likelihood for upgrade at a separate site of ipsilateral concurrent ADH above contemporary reported upgrade rates of ADH alone (10-30%). When considering breast conservation for breast cancer, omitting excision of the site of ADH can be considered when low-risk features are present.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Amin AL
Department of Surgery, The University of Kansas Health System, Kansas City, KS, USA. aamin5@kumc.edu.
Fan F
Department of Pathology, The University of Kansas Health System, Kansas City, KS, USA.
Winblad OD
Department of Radiology, The University of Kansas Health System, Kansas City, KS, USA.
Larson KE
Department of Surgery, The University of Kansas Health System, Kansas City, KS, USA.
Wagner JL
Department of Surgery, The University of Kansas Health System, Kansas City, KS, USA.

MeSH

Biopsy, Large-Core NeedleBreastBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleHumansHyperplasiaRetrospective Studies

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32705514

Citation

Amin, Amanda L., et al. "Ipsilateral and Concurrent Breast Cancer and Atypical Ductal Hyperplasia: Does Atypia Also Need Surgical Excision?" Annals of Surgical Oncology, vol. 27, no. 12, 2020, pp. 4786-4794.
Amin AL, Fan F, Winblad OD, et al. Ipsilateral and Concurrent Breast Cancer and Atypical Ductal Hyperplasia: Does Atypia Also Need Surgical Excision? Ann Surg Oncol. 2020;27(12):4786-4794.
Amin, A. L., Fan, F., Winblad, O. D., Larson, K. E., & Wagner, J. L. (2020). Ipsilateral and Concurrent Breast Cancer and Atypical Ductal Hyperplasia: Does Atypia Also Need Surgical Excision? Annals of Surgical Oncology, 27(12), 4786-4794. https://doi.org/10.1245/s10434-020-08896-7
Amin AL, et al. Ipsilateral and Concurrent Breast Cancer and Atypical Ductal Hyperplasia: Does Atypia Also Need Surgical Excision. Ann Surg Oncol. 2020;27(12):4786-4794. PubMed PMID: 32705514.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ipsilateral and Concurrent Breast Cancer and Atypical Ductal Hyperplasia: Does Atypia Also Need Surgical Excision? AU - Amin,Amanda L, AU - Fan,Fang, AU - Winblad,Onalisa D, AU - Larson,Kelsey E, AU - Wagner,Jamie L, Y1 - 2020/07/23/ PY - 2020/05/14/received PY - 2020/06/27/accepted PY - 2020/7/25/pubmed PY - 2021/5/5/medline PY - 2020/7/25/entrez SP - 4786 EP - 4794 JF - Annals of surgical oncology JO - Ann Surg Oncol VL - 27 IS - 12 N2 - BACKGROUND: Standard-of-care management of atypical ductal hyperplasia (ADH) is surgical excision. Multiple studies have identified features of ADH in patients at low risk for upgrade who may benefit from omission of surgical excision. Patients with an ipsilateral breast cancer have been excluded from studies investigating observation for the management of ADH. METHODS: This was a retrospective review of women with both a breast cancer and an ipsilateral separate site of ADH diagnosed on percutaneous biopsy, who underwent excision of both sites from 2008 to 2018. Radiographic and pathologic features of ADH and cancer were analyzed, including imaging size, biopsy modality, distance between sites, cancer subtype, grade, prognostic markers, ADH foci, and presence of necrosis or micropapillary features. Final pathology at the ADH site was used to determine upgrade. Multivariable logistic regression was performed to identify variables significantly associated with ADH upgrade to malignancy. RESULTS: Among 62 women meeting the inclusion criteria, 11 (17.7%) upgraded to malignancy [9 ductal carcinoma in situ (DCIS), 2 invasive cancer] at the site of ADH. Upgrade was significantly higher with ipsilateral DCIS (p = 0.03), ultrasound biopsy at the ADH site (p = 0.01), and ADH with necrosis (p = 0.04). The group at lowest risk for upgrade had stereotactic biopsy and ADH without necrosis (0% upgrade). CONCLUSION: The presence of breast cancer does not significantly increase the likelihood for upgrade at a separate site of ipsilateral concurrent ADH above contemporary reported upgrade rates of ADH alone (10-30%). When considering breast conservation for breast cancer, omitting excision of the site of ADH can be considered when low-risk features are present. SN - 1534-4681 UR - https://www.unboundmedicine.com/medline/citation/32705514/Ipsilateral_and_Concurrent_Breast_Cancer_and_Atypical_Ductal_Hyperplasia:_Does_Atypia_Also_Need_Surgical_Excision DB - PRIME DP - Unbound Medicine ER -